↓ Skip to main content

Genitourinary Cancers

Overview of attention for book
Attention for Chapter 11: Current Role of Checkpoint Inhibitors in Urologic Cancers
Altmetric Badge

Mentioned by

twitter
2 X users

Readers on

mendeley
9 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Chapter title
Current Role of Checkpoint Inhibitors in Urologic Cancers
Chapter number 11
Book title
Genitourinary Cancers
Published in
Cancer treatment and research, September 2018
DOI 10.1007/978-3-319-93339-9_11
Pubmed ID
Book ISBNs
978-3-31-993338-2, 978-3-31-993339-9
Authors

Attalla, Kyrollis, Sfakianos, John P, Galsky, Matthew D, Kyrollis Attalla, John P. Sfakianos, Matthew D. Galsky, Sfakianos, John P., Galsky, Matthew D.

Abstract

Harnessing the host immune system to combat genitourinary cancers has key theoretical advantages over other anticancer strategies including specificity and memory which should translate to favorable tolerability and response durability in the clinic. Indeed, key examples of the potential for immunotherapeutic treatment of solid tumors are derived from data in genitourinary cancers including Bacillus Calmette-Guerin for urothelial cancer, sipuleucel-T for prostate cancer, and interleukin-2 for renal cancer. Despite these successes, developing effective immunotherapeutic strategies for the treatment of cancer has largely been hampered by an incomplete understanding of tumor immunobiology and mechanisms of immune resistance. In just a few years since entering the clinic, immune checkpoint blockade has dramatically changed the landscaped of treatment for genitourinary cancer and has secured a place as a standard pillar of treatment. Further iterative bench-bedside-bench research is anticipated to extend the benefits of immunotherapeutic-based approaches to additional patients.

X Demographics

X Demographics

The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 9 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 9 100%

Demographic breakdown

Readers by professional status Count As %
Other 2 22%
Student > Bachelor 1 11%
Unspecified 1 11%
Student > Postgraduate 1 11%
Lecturer 1 11%
Other 0 0%
Unknown 3 33%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 2 22%
Medicine and Dentistry 2 22%
Nursing and Health Professions 1 11%
Unspecified 1 11%
Unknown 3 33%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 20 June 2019.
All research outputs
#17,989,170
of 23,102,082 outputs
Outputs from Cancer treatment and research
#118
of 167 outputs
Outputs of similar age
#240,951
of 335,775 outputs
Outputs of similar age from Cancer treatment and research
#1
of 3 outputs
Altmetric has tracked 23,102,082 research outputs across all sources so far. This one is in the 19th percentile – i.e., 19% of other outputs scored the same or lower than it.
So far Altmetric has tracked 167 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.2. This one is in the 24th percentile – i.e., 24% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 335,775 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 23rd percentile – i.e., 23% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 3 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them